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Abstract
Background: Medication-related problems are common in older adults with multiple chronic conditions. We
evaluated the impact of a nurse-based primary care intervention, based on the Guided Care model of care, on
patient-centered aspects of medication use.
Methods: Controlled clinical trial of the Comprehensive Care for Multimorbid Adults Project (CC-MAP), conducted
among 1218 participants in 7 intervention clinics and 6 control (usual care) clinics. Inclusion criteria included age
45–94, presence of ≥3 chronic conditions, and Adjusted Clinical Groups (ACG) score > 0.19. The co-primary
outcomes were number of changes to the medication regimen between baseline and 9 month followup, and
number of changes to symptom-focused medications, markers of attentiveness to medication-related issues.
Results: Mean age in the intervention group was 72 years, 59% were women, and participants used a mean of 6.6
medications at baseline. The control group was slightly older (73 years) and used more medications (mean 7.1).
Between baseline and 9 months, intervention subjects had more changes to their medication regimen than control
subjects (mean 4.04 vs. 3.62 medication changes; adjusted difference 0.55, p = 0.001). Similarly, intervention subjects
had more changes to their symptomatic medications (mean 1.38 vs. 1.26 changes, adjusted difference 0.20, p = 0.003).
The total number of medications in use remained stable between baseline and follow-up in both groups (p > 0.18).
Conclusion: This nurse-based, primary care intervention resulted in substantially more changes to patients’ medication
regimens than usual care, without increasing the total number of medications used. This enhanced rate of change
likely reflects greater attentiveness to the medication-related needs of patients.
Trial registration: This trial is registered at https://clinicaltrials.gov, trial number NCT01811173.
Keywords: Polypharmacy, Medication management, Primary care, Israel, Aged, Multimorbidity, Quality of care
Background
Prescribing for older adults with multiple chronic condi-
tions often leads to medication regimens that are overly
complicated, difficult to adhere to, and contain multiple
drug-drug and drug-disease interactions [1, 2]. In addition,
prescribing decisions often do not attend to patient
preferences, abilities, and goals of care [3]. This leaves
patients feeling sidelined and disengaged from their care,
with medication regimens that are not tailored to their
needs and preferences [4].
Addressing these patient-centered issues requires
patient-centered approaches to improving medication
use. Such strategies use an understanding of patients’
needs and abilities to inform treatment decisions [5]. In
addition, these strategies can help patients adhere to and
properly use medications to maximally benefit their
health and achieve their goals [6]. Yet, this is easier said
than done. Programs such as patient-centered medical
homes are promising but have shown mixed results, and
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there are few models of care that consistently achieve
these ends and are practical for widespread use [7].
In recent years, a promising new model called Guided
Care has been proposed that is well suited to address
these needs [8]. Guided Care is a system of comprehen-
sive, interdisciplinary care that is tailored to the needs of
older adults with multiple chronic conditions [9]. In this
model, a registered nurse based in a primary care clinic
works with a panel of vulnerable older patients. The
nurse interfaces with these patients via home visits, over
the telephone, and in the clinic. These interactions
include elements of case management, support for pa-
tient self-management, and help with transitions of care.
The nurse also works with patients’ clinicians to help
coordinate care and bring patients’ needs, abilities, and
preferences to clinical decision-making. Although it was
not designed specifically to improve medication use,
and does not incorporate any structured elements
that focus explicitly on medications (such as medica-
tion review or reconciliation), its philosophy and pro-
cesses are tightly aligned with the pharmaceutical care
needs of older adults [10].
Previous studies have evaluated the impact of Guided
Care on several outcomes such as mortality, mental and
physical health, and caregiver burden [11–16]. However,
little work has been done on how Guided Care impacts
medication use and outcomes in vulnerable older adults.
To fill this important evidence gap, we evaluated the
effect of an intervention based on the Guided Care
model on several aspects of medication prescribing for
older adults in Israel. We hypothesized that older adults
receiving this intervention would have improved markers
of patient-centered prescribing – namely, more changes
to their overall medication regimens, and more changes to
their symptom-focused medications, representing greater
attentiveness to adjusting medication regimens in re-
sponse to patient symptoms, challenges with existing
medications, and goals of care.
Methods
Intervention and study population
This study uses data from the Comprehensive Care for
Multimorbid Adults Project (CC-MAP), a controlled
clinical trial of a nurse-based intervention that was con-
ducted within primary care clinics of Clalit Health Sys-
tems [17]. Clalit is Israel’s largest integrated health care
provider and insurer, serving approximately half the
country’s population.
In the CC-MAP study, representative (but not ran-
domized) primary care clinics within 2 regions of Israel
were selected as intervention and control sites. In the 7
intervention sites, nurses trained in the CC-MAP model
were embedded in a clinic, which typically comprised 3
to 4 physicians plus support staff. CC-MAP nurses
followed a panel of vulnerable adults who met the inclu-
sion/exclusion criteria outlined below. Six control clinics
were selected with similar demographic and health
system characteristics as the intervention clinics. In the
control clinics, patients received usual care.
Intervention patients met with the CC-MAP nurse
monthly in person or by phone, and in person at least
once per quarter, to review their care plan, make adjust-
ments and receive counseling as needed, and follow up.
When a patient was hospitalized, the CC-MAP nurse
contacted the patient immediately after discharge to
review changes in treatment recommendations, and as
needed alert the primary care physician to implement
treatment changes described in discharge recommenda-
tions. As this complex intervention was tailored to the
needs and preferences of each participant, some subjects
received more intensive services and contacts than
others, although all intervention subjects enrolled had a
minimum of 3 contacts (in person or by telephone) with
CC-MAP nurses per year, with most having substantially
more. There was no specific medication reconciliation
or pharmacy component to the intervention, although
since the nurse was part of a nurse-primary care phys-
ician team, part of her role was to periodically assess the
patient’s status, including adherence to the care plan.
Thus, when the nurse identified that the patient had side
effects from medications, or that he/she was not adher-
ing to the treatment, she notified the primary care phys-
ician. This provided an opportunity to be able to tailor
care to patients’ evolving status and needs.
Inclusion criteria included community-dwelling adults
age 45–94 years and the presence of 3 or more chronic
conditions. In addition, we employed a Johns Hopkins
Adjusted Clinical Group® (ACG) system predictive mod-
eling score using diagnosis and pharmacy data (the
DxRxPM model), restricting enrollment to people
with a score > 0.19, indicating high risk of poor clin-
ical outcomes [18]. Exclusion criteria included inabil-
ity to speak Hebrew or Russian, current participation
in a disease management program, use of dialysis or
chemotherapy, advanced dementia, or severe mental
illness such as schizophrenia (see Fig. 1). Over 70% of
the study population was age 65 and older. Interven-
tion subjects were enrolled between April 2013 and
June 2014, and control subjects between November
2013 and March 2015.
Measures
The pre-specified primary outcome of the CC-MAP trial
was hospital admissions for ambulatory-sensitive condi-
tions, which the trial was powered to detect with an
effect size of 0.3 and a type I error of 0.05. After the trial
commenced but prior to reviewing outcomes data, we
selected 2 new outcomes of interest related to medications,
Steinman et al. BMC Geriatrics  (2018) 18:207 Page 2 of 9
listed below. We chose these outcomes based on domains
where we hypothesized the CC-MAP intervention could
have particularly beneficial impacts on medication use. We
considered these 2 outcomes co-primary for purposes of
this study.
Medication use was assessed using pharmacy dispens-
ing data from Clalit pharmacies and from non-Clalit
pharmacies where Clalit insurance was billed. To-
gether these account for the strong majority of pre-
scription medications filled by Clalit members, who
have powerful financial incentives to fill their medica-
tions using their Clalit benefits [19, 20]. We employed
a variant of methods recommended by Lund et al. to
identify prevalent medication use at time points of
interest [21]. Because it can be difficult to ascertain
dose and duration of medications that are delivered topic-
ally or locally, we restricted our analyses to medication
classes that are delivered systemically and/or have sys-
temic effects.
Outcome #1 - Number of changes in medication regimen
We hypothesized that the CC-MAP intervention would
lead to more changes in medication regimens by im-
proving communication about patient symptoms, goals,
and problems with existing treatment regimens. Based
on prior work, we defined medication changes as the
sum of medication additions (medications present at
9 months that were not present at baseline), medication
discontinuations (medications present at baseline that
were no longer present at 9 months), therapeutic substi-
tutions (a switch from one medication to another within
the same drug class, defined at the 4th level of the Ana-
tomic Therapeutic Classification [ATC] system), and
Fig. 1 CONSORT diagram. People who died within the first 9 months after enrollment could not be analyzed since 9-month medication outcome
data were not available for these subjects
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dose changes (the same medication given at different
daily doses at baseline vs. 9 months) [22].
Outcome #2 – Change in use of symptom-focused
medications
We hypothesized that improved communication about
patient symptoms would lead to more fine-tuning of
symptom-focused medications. Our co-primary outcome
was the number of changes in symptom-focused
medications between baseline and 9 months. A sec-
ondary outcome was the total number of symptom-
focused medications in use at 9 months. Methods
for defining symptom-focused medications are de-
scribed in Additional file 1: Appendix S1.
Other variables
Patient demographics were collected from Clalit data
systems. Comorbid conditions were assessed using algo-
rithms developed for Clalit clinical and claims data, for
example using inpatient and outpatient diagnoses, phar-
macy records, and laboratory test results. The unweighted
sum of 27 chronic conditions defined a patient-level
comorbidity score. ACG scores were calculated using
clinical and claims data using standard methods employed
by Clalit and validated for CC-MAP patient selection
[23, 24]. Higher ACG scores predict a variety of poor
clinical outcomes [24].
Main analyses
Our analyses used an intention to treat framework.
Overall, 45 intervention subjects and 1 control subject
withdrew from participation in the intervention and/or
followup assessments between baseline and 9 months,
and 3 intervention subjects moved to a different clinic.
(The differential drop-out rate is likely explained by bur-
den and/or dislike of the intervention by intervention
subjects, whereas control subjects had only usual care.)
Although these subjects withdrew from participation or
moved, we were able to assess their medication out-
comes as medication use was measured using pharmacy
claims data, which were generated irrespective of trial
participation. Thus, these subjects were included in the
final analysis according to their original treatment
assignment.
All analyses employed mixed effects regression, using
random effects to adjust for clustering of study subjects
within physicians, and fixed effects to adjust for region.
Clinic-level random effects were negligible after account-
ing for physician random effects. Outcomes analyses
controlled for potential confounders including age, sex,
comorbidity count, ACG DxRxPM score, number of
medications present at baseline, and the number of
medication changes that had occurred between 9 months
before baseline and baseline (to account each subject’s
pre-baseline rate of medication changes). We used inter-
action terms to evaluate potential effect modification
among pre-specified subgroups defined by age, ACG
predictive modeling score, and number of medications
used at baseline.
The enrollment period for intervention subjects began
and ended earlier than the enrollment period for control
subjects, with only partial overlap. To evaluate if secular
trends could have impacted our results, we assessed
the impact of enrollment time on our medication out-
comes in each treatment group. In these analyses,
enrollment time was not associated with outcomes in
either group (p > .15 for all).
Exploratory analyses
We conducted an exploratory analysis to understand
the relationship between our primary outcome meas-
ure (number of medication changes) and patient-cen-
teredness. We hypothesized that a greater number of
medication changes over time would be associated
with greater patient-centeredness, reflecting increased
attention to patients’ medication-related needs and
challenges. This analysis used data from the Patient
Assessment of Chronic Illness Care (PACIC) ques-
tionnaire, which was completed by control subjects at
baseline. (Accurate baseline data were not available
for intervention subjects). Our predictor variable was
the number of medication changes in the 9 months
prior to the time the PACIC was administered. Our
outcome variable was the sum of scores for the first
3 items on the PACIC questionnaire, which address
the patient-centeredness of treatment planning, and
which have been validated to have strong psychomet-
ric properties (Cronbach’s alpha 0.82, standardized
factor loadings > 0.75) [25]. Answers to these items
were summed into a score ranging from 3 (never in-
volved in treatment planning) to 15 (always involved
in treatment planning). We used Poisson regression
to evaluate the predictor-outcome relationship, while
controlling for potential confounders including num-
ber of medications in the pre-baseline period, number
of chronic conditions, ACG predictive modeling score,
age, race, and sex, and adjusting for clinician as a random
effect (see Additional file 1: Appendix S5).
This study adheres to CONSORT guidelines and was
approved by the institutional review boards of Clalit
Health Services and the University of California, San
Francisco.
Results
Subject enrollment and follow-up data are shown in
Fig. 1. Of 1230 subjects enrolled, 1218 had full data
available for analysis at 9 month follow-up. The 622
intervention patients in the final analytic sample
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received care in 7 intervention clinics by 21 primary
care physicians. The 598 control patients received
care in 6 control clinics predominantly by 17 primary
care physicians.
Baseline characteristics of intervention control patients
are shown in Table 1. Compared with control patients,
intervention patients were slightly younger, had fewer
chronic conditions, and received fewer medications.
Effect of CC-MAP intervention on changes in medication
use
Between baseline and 9 months, intervention patients
had a mean of 4.04 changes to their medication regimens
(Table 2). Control patients had a mean of 3.62 changes.
After adjusting for baseline characteristics, intervention
patients had a mean of 0.55 more medication changes
than control subjects (p = .001; see Additional file 1:
Appendix S3 for additional information).
A similar pattern was observed for changes in the
use of symptom-focused medications. Between base-
line and 9 month followup, intervention patients had
more changes to their regimen of symptom-focused
medications than control patients (mean 1.38 vs.
1.27 changes, adjusted mean difference 0.20 changes,
p = .003).
As a sensitivity analysis, we expanded our definition of
symptom-focused medications to include drugs used to
treat intermittent but highly symptomatic conditions,
and medications with mixed symptom-focused and
non-symptom-focused uses. Results were similar using
this expanded definition: intervention patients had more
changes to the regimen of symptom-focused medications
than control patients (mean 1.89 vs 1.81 changes, ad-
justed mean difference 0.20 changes, p = .01).
Characteristics of medication changes
In both the intervention and control groups, there was
little difference in the total number of medications
subjects used at baseline and at 9 months. The interven-
tion group used a mean of 0.09 more medications at
9 months compared with baseline (p = 0.32 for change).
The control group used a mean of 0.12 fewer medica-
tions at 9 months compared with baseline (p = 0.18 for
change; p = .12 for difference in change between inter-
vention and control groups).
The total number of symptom-focused medications
also remained generally stable from baseline to 9 months,
although there was a small, statistically significant
increase in the intervention group. The intervention
group used a mean of 0.13 more symptom-focused
medications at 9 months compared with baseline (p =
0.02 for change). The control group used 0.03 fewer
symptom-focused medications at 9 months (p = 0.59 for
change; p = 0.06 for difference in number of changes be-
tween groups).
The distribution of types of medication changes (e.g.
additions, discontinuations, therapeutic substitutions,
and dose changes) were generally similar across groups
(Table 3). The distribution of which classes of drugs
were changed was also similar in the two groups. The
most commonly changed medication class was cardio-
vascular medications, which accounted for 30% of
changes in the intervention group and 29% in the con-
trol group (p = 0.31 for difference; see Additional file 1:
Appendix S4 for additional information).
Subgroup effects
The impact of the intervention on both medication
change outcomes did not vary between patients of differ-
ent age (under 75 vs. 75 or more years), ACG score
Table 1 Baseline characteristics of intervention and control subjects
Intervention N = 622 Control N = 596
Age (mean, SD) 71.6 (10.2) 73.4 (9.9)
Female sex 365 (59) 329 (55)
No. of chronic conditions (mean, SD)a 4.1 (2.1) 4.8 (2.3)
ACG score (median, IQR)b 0.29 (0.22–0.42) 0.25 (0.18–0.39)
Number of medications at baseline (mean, SD) 6.6 (3.3) 7.1 (3.2)
Number of changes in medications in the 9 months prior to baseline 3.9 (2.7) 3.9 (2.8)
Number of symptom-focused medications at baseline
0 203 (33) 150 (25)
1 161 (26) 165 (28)
2 or more 258 (41) 281 (47)
p value < 0.05 for difference between groups for age, number of chronic conditions, ACG score, and number of medications (overall and symptom-focused)
at baseline
a From a list of 27 chronic conditions
b ACG scores for some subjects are below the enrollment threshold because these scores shifted between the time these subjects were identified as eligible to
participate to the time they were enrolled
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(under 0.27 vs. 0.27 or greater), number of medications
at baseline (under 7 vs 7 or more), and number of
symptom-focused medications at baseline (0 to 1 vs. 2
or more), with p values for interaction > 0.37 in each
comparison.
Exploratory analyses
In an exploratory analysis, we used data from the control
group to evaluate the relationship between number of
medication changes and the patient-centeredness of
treatment planning. On a scale of 3–15 (with 15 being
best), the median 3-item PACIC score was 6 (interquar-
tile range, 3–9). There was a non-linear relationship
between number of medication changes and 3-item
PACIC scores. Compared to subjects with 0–2 medica-
tion changes, 3-item PACIC scores were a mean of 0.30
points higher in subjects with 3–5 medication changes,
but 0.44 points lower in subjects with 6 or more changes
(p = 0.003 for difference in scores between categories).
After controlling for several potential confounders, the
differences remained (p = .03; see Additional file 1:
Appendix S5 for details).
Discussion
In this controlled clinical trial, the CC-MAP interven-
tion – a nurse based, primary care intervention based on
the Guided Care model of care – improved several
aspects of prescribing in vulnerable Israeli adults. Com-
pared with usual care, patients receiving the CC-MAP
intervention had more changes to their medication
regimens in general, and more changes in their symp-
tom-focused medications. This increased rate of changes
may reflect more attentive management to patients’
medication-related needs.
Our findings build on prior research on the Guided
Care model of care. Past studies have shown that Guided
Care improves patient-centered processes of care, in-
cluding goal-setting, coordination of care, decision sup-
port, and patient activation [11–14]. This study adds a
new dimension to these findings by improving markers
of patient-centered medication management. However,
despite benefits in processes of care, a large trial of
Guided Care did not demonstrate significantly beneficial
effects on health outcomes including self-reported
measures of physical and mental health, mortality, and
several forms of health services utilization [15, 16]. Al-
though these findings are disappointing, they are not the
last word. The trial was underpowered to detect small
but clinically meaningful differences in these outcomes,
and provided lessons about potential future improve-
ments in this care model [15, 16]. Subsequent work test-
ing refined models of Guided Care are underway,
including the CC-MAP trial, which is showing promise
for improving these hard outcomes.
One noteworthy aspect of our findings is that improv-
ing medication use was not a primary goal of the inter-
vention, and in fact the CC-MAP program had no
structured elements that focused explicitly on medica-
tions. Rather, the improved markers of medication use
that we observed appear to be a beneficial “side effect”
Table 2 Number of medication changes between baseline and 9 months, intervention vs. control group
Intervention N = 622 Control N = 596 Adjusted difference in number
of medication changesa
p value
Total number of changes to medication
regimen (mean, SD)
4.04 (2.8) 3.62 (2.7) 0.55 .001
Total number of changes of symptom-focused
medications (mean, SD)
1.38 (1.5) 1.27 (1.5) 0.20 .003
a Adjusted for baseline subject characteristics and clustering
Table 3 Types of medication changes between baseline and 9 months, intervention vs. control group
Types of medication change Intervention
N = 622
Mean # of changes (% of total)a
Control
N = 596
Mean # of changes
(% of total)a
Adjusted differenceb p value
Medication additions 1.79 (44%) 1.51 (42%) 2% 0.37
Medication discontinuations 1.70 (42%) 1.63 (45%) 3% 0.09
Therapeutic substitutions 0.15 (4%) 0.15 (4%) 0% 0.91
Dose increases 0.18 (5%) 0.19 (6%) 1% 0.39
Dose reductions 0.21 (6%) 0.15 (4%) 2% 0.007
TOTAL NUMBER OF CHANGES 4.04 (100%) 3.62 (100%) – –
a Results show the mean number of each type of medication change within each group, and the percent of all changes attributable to each type of change
b Difference between intervention and control group in the percent of changes attributable to each type of change. Adjusted for baseline subject characteristics
and clustering
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of the more general goals of the CC-MAP program such
as improving communication and care coordination.
Vulnerable older adults require support in many areas,
for example improving pharmacotherapy, assessing and
maintaining functional and cognitive abilities, and much
more [26]. Yet, it is impractical to offer multiple discrete
interventions, each targeted to only one area [27]. In
being able to improve a domain of care that was not an
explicit focus of the intervention, CC-MAP and Guided
Care show promise as a single intervention which that
can favorably affect multiple domains.
The first two measures of prescribing that we evalu-
ated – the number of changes in medications overall,
and the number of changes in symptom-focused medica-
tions – are not standard measures of prescribing quality,
and have not been validated as markers of this construct.
Thus, we cannot be sure that the higher number of
changes observed in the intervention group represents
better care. Our analyses between number of medication
changes and treatment-planning components of the
PACIC score suggest there may be a threshold effect: a
moderate number of changes are associated with more
patient-centered care, but a large volume of changes has
the opposite effect. However, this finding should be con-
sidered preliminary, since it used only a subset of the
PACIC score and was unable to control for potentially
important confounders.
Although these caveats are important, these markers
nonetheless have potential to be valuable [22]. Many
commonly used markers of prescribing quality, such as
prescribing of drugs to avoid in older adults (e.g. the
Beers and STOPP criteria) are not particularly patient-
centered [28, 29]. What often matters most for patients
is individualizing their medication regimen to suit
their particular circumstance, yet studies have shown
that clinical inertia and competing demands often
prevent appropriate modification of regimens to
meet changing patient needs [30–32]. Although more
changes are not always better, in this context they
may reflect more attention to individual patient cir-
cumstances [33].
Additional findings also shed light on the meaning of
the increased rate of medication changes observed in the
intervention group. The total number of medications
used by intervention subjects remained stable despite
the higher number of medication changes. The interven-
tion thus appears to have enhanced “fine-tuning” of
medications rather than adding to the already-large
numbers of medications used by study subjects. It is also
noteworthy that the intervention did not preferentially
affect one type of medication change or one class of
medications. This appears to reflect a generalized ef-
fect of the intervention rather than focused changes
in one specific area.
Our study has several limitations. Due to practical
considerations the selection of intervention and control
clinics was not random. However, we were able to con-
trol for multiple baseline characteristics of subjects,
including their pre-baseline rate of medication changes,
which substantially reduces potential for bias in our
results. Medication use was ascertained using pharmacy
dispensing records. As a result, our measures of medica-
tion use are affected both by what medications the
physician(s) ordered and patients’ adherence to obtain-
ing those medications; we are unable to distinguish the
relative contribution of each. Nonetheless, this does not
affect our conclusions since both physician prescribing
and patient adherence are important facets of medica-
tion use that may be improved by the intervention. In
addition, we were unable to account for medications not
captured in Clalit databases. However, this likely ac-
counts for only a small fraction of medications filled,
given strong incentives to fill medications using Clalit
insurance benefits, and is unlikely to differ between
intervention and control subjects. Finally, we did not
evaluate the impact of the intervention on clinical
outcomes such as medication errors, hospitalizations, or
symptom control; these will be important avenues for
future research.
Conclusions
The CC-MAP intervention, a nurse-based primary care
program based on the Guided Care model of care,
improved markers of patient-centered prescribing in
vulnerable adults. With further attention to medication-
related issues, this program – which had little explicit
focus on medication use – might further improve pre-
scribing and improve medication-related outcomes in
vulnerable older adults.
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